EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

FOXP3 +/ CD8 + ratio associated with aggressive behavior in RUNX3 ‐methylated diffuse esophagogastric junction tumor

Suguru Maruyama, Yu Imamura iD, Tasuku Toihata, Ikumi Haraguchi, Manabu Takamatsu iD, Makiko Yamashita, Yuichiro Nakashima, Eiji Oki iD, Kenichi Taguchi, Manabu Yamamoto, Shinji Mine, Akihiko Okamura und 6 weitere

Cancer Science · 2025

DOI: 10.1111/cas.16373 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Suguru Maruyama und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Forkhead Transcription Factors, Esophagogastric Junction, Core Binding Factor Alpha 3 Subunit, Adenocarcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Uehara Memorial Foundation, Japan Research Foundation for Clinical Pharmacology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The tumor immune microenvironment is increasingly becoming a key consideration in developing treatment regimens for aggressive cancers, with evidence that regulatory T cells (Tregs) attenuate the antitumor response by interrupting cytotoxic T cells (CD8+). Here, we hypothesized the prognostic relevance of the proportions of Tregs (marked by forkhead box protein 3 [FOXP3]) and CD8+ cells in diffuse, non‐Epstein–Barr virus (EBV)/non‐microsatellite instability (MSI)‐high gastroesophageal adenocarcinomas (GEAs), which are clinically characterized as more aggressive, immunologically inactive tumors as compared with their intestinal counterparts. Cell‐count ratios of FOXP3+/CD8+ expression were calculated at the intratumoral region and invasive margin discretely on digital images from 303 chemo‐naive non‐EBV/non‐MSI‐high esophagogastric junction (EGJ) adenocarcinomas. A significant modifying prognostic effect of tumor histology was observed between 5‐year EGJ cancer‐specific survival and the FOXP3+/CD8+ ratio at the invasive margin in pStage I–III tumors ( p for interaction = 0.022; hazard ratio [HR] = 8.47 and 95% confidence interval [CI], 2.04–35.19 for high ratio [vs. low] for diffuse; HR = 1.57 and 95% CI, 0.88–2.83 for high ratio [vs. low] for intestinal). A high FOXP3+/CD8+ ratio at the invasive margin was associated with RUNX3 methylation ( p = 0.035) and poor prognosis in RUNX3 ‐methylated diffuse histological subtype (5‐year EGJ cancer‐specific survival, 52.3% for high and 100% for low, p = 0.015). Multiomics data from The Cancer Genome Atlas linked CCL28 with RUNX3 ‐suppressed diffuse histological subtypes of non‐EBV/non‐MSI‐high GEA. Our data suggest that a high FOXP3+/CD8+ ratio at the invasive margin might indicate tumor immune escape via CCL28, particularly in the RUNX3 ‐methylated diffuse histological subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Forkhead Transcription FactorsEsophagogastric JunctionCore Binding Factor Alpha 3 SubunitAdenocarcinomaCD8-Positive T-LymphocytesStomach NeoplasmsEsophageal NeoplasmsTumor MicroenvironmentHumansMaleFemaleMiddle AgedAgedPrognosisT-Lymphocytes, RegulatoryDNA MethylationMicrosatellite InstabilityAdultAged, 80 and overLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

chemokinediffuse histologyeffector T cellesophagogastric junction adenocarcinomaregulatory T cell

Substanzen

Forkhead Transcription FactorsCore Binding Factor Alpha 3 SubunitFOXP3 protein, humanRunx3 protein, human

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Pathology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Advanced Medical Development Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

ORCID-Profile: Yu Imamura, Manabu Takamatsu, Eiji Oki, Shigehisa Kitano

Förderung

  • Japan Society for the Promotion of Science
  • Uehara Memorial Foundation
  • Japan Research Foundation for Clinical Pharmacology
  • Foundation for Promotion of Cancer Research

Zitieren

APA

Maruyama, S., Imamura, Y., Toihata, T., Haraguchi, I., Takamatsu, M., Yamashita, M., Nakashima, Y., Oki, E., Taguchi, K., Yamamoto, M., Mine, S., Okamura, A., Kanamori, J., Nunobe, S., Sano, T., Kitano, S., Noda, T., & Watanabe, M. (2025). FOXP3 +/ CD8 + ratio associated with aggressive behavior in RUNX3 ‐methylated diffuse esophagogastric junction tumor. Cancer Science. https://doi.org/10.1111/cas.16373

Vancouver

Maruyama S, Imamura Y, Toihata T, Haraguchi I, Takamatsu M, Yamashita M, et al. FOXP3 +/ CD8 + ratio associated with aggressive behavior in RUNX3 ‐methylated diffuse esophagogastric junction tumor. Cancer Science. 2025. doi:10.1111/cas.16373

BibTeX
@article{Maruyama2025,
  author = {Maruyama, Suguru and Imamura, Yu and Toihata, Tasuku and Haraguchi, Ikumi and Takamatsu, Manabu and Yamashita, Makiko and Nakashima, Yuichiro and Oki, Eiji and Taguchi, Kenichi and Yamamoto, Manabu and Mine, Shinji and Okamura, Akihiko and Kanamori, Jun and Nunobe, Souya and Sano, Takeshi and Kitano, Shigehisa and Noda, Tetsuo and Watanabe, Masayuki},
  title = {FOXP3 +/ CD8 + ratio associated with aggressive behavior in RUNX3 ‐methylated diffuse esophagogastric junction tumor},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.16373}
}
Kostenlos starten →